- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07609433
Mitigation of Health Effects in Pregnant Women by Reducing Exposure to Heat and Air Pollution (ISMED CLIM PW)
Innovative Solutions Across the MEDiterranean for Mitigation of Climate Change-related heaLth rIsks and Enhancing Health systeM Resilience in Pregnant Women
The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in pregnant women.
The main questions it aims to answer are:
- Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)?
- Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)?
- Does the intervention (combination of behavioral recommendations for heat mitigation) reduce sleep difficulties experienced by pregnant women, measured using the Pittsburgh Sleep Quality Index?
Researchers will compare measurements between pregnant women carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups.
Participants will:
- Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months
- Have their core temperature measured using an eCelsius medical capsule in three repeated assessments
- Complete the Pittsburgh Sleep Quality Index questionnaire in three repeated assessments
- Provide samples of urine and blood biomarkers in three repeated assessments.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Panayiotis Yiallouros, Professor
- Telefonní číslo: +35722895212
- E-mail: yiallouros.panayiotis@ucy.ac.cy
Studijní záloha kontaktů
- Jméno: Panayiotis Kouis, PhD
- Telefonní číslo: +35722895243
- E-mail: kouis.panayiotis@ucy.ac.cy
Studijní místa
-
-
-
Catania, Itálie
- Nábor
- Azienda Ospedaliera Di Rilievo Nazionale Garibaldi Catania
-
Kontakt:
- Antonella Agodi
- Telefonní číslo: +390953782183
- E-mail: antonella.agodi@unict.it
-
-
-
-
-
Limassol, Kypr
- Nábor
- Medical School, University of Cyprus
-
Kontakt:
- Panayiotis Kouis
- Telefonní číslo: +35722895243
- E-mail: kouis.panayiotis@ucy.ac.cy
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Pregnant Women (PW) aged 20 to 35 years
- being in the 2nd trimester of a singleton pregnancy (15th-27th week of gestation)
- Living in Catania (Italy) or Limassol (Cyprus) districts
- Clinically healthy
- No Gestational diabetes
- No pre-eclampsia
- No severe pregnancy complications
Exclusion Criteria:
- Currently smoking
- Presence of any smoking residents in the household
- Not residing at the household for at least 5 days a week
- Planning to move from the current home within the next two months
- No access to Wi-Fi or 4G/5G mobile phone
- Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, DM2, inflammatory diseases, renal failure, or active cancer)
- Drugs abuse
- Alcohol abuse
- Psychiatric disorders
- Severe mental disability that interferes with answering questions or following instructions
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Heat and air pollution intervention - Group Alerts, Recommendations and Air Cleaners
Subjects in this group will receive alerts and recommendations as in group "Heat intervention" and in addition, continuously use of air cleaners with HEPA filter for removing PM from indoor air in their residences and workplaces to provide evidence for health benefits.
|
The participants in this intervention group will receive alerts and recommendations as in group "Heat intervention" and, in addition, continuously use air cleaners with HEPA filters for removing PM from indoor air in their residences and workplaces.
Ostatní jména:
|
|
Žádný zásah: Control group
Subjects in this arm will receive no alerts forhigh temperatures nor recommendations formitigation of heat-related health effects.
|
|
|
Experimentální: Heat intervention - Personal Alerts and Specific Recommendations
Subjects in this group will receive timelypersonal alerts for high temperatures and specific recommendations to reduce exposure to heat and mitigation of heat-related health effects in written and animated format through mobile phones ,mobile applications and online tools.
|
The participants in this group of intervention will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and/or air conditioning devices, as well as recommendations for mitigation of heat-related health effects (hydration, body cooling) in written and animated format, through mobile phones, web application and online tools to be developed by the project research team
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI)
Časové okno: The PSQI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a one-month time interval.
The PSQI is commonly used in both clinical and research settings to evaluate various aspects of sleep.
It is a valuable tool for assessing sleep quality as it captures multiple dimensions of sleep, including both subjective experiences and objective parameters.
Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.
|
The PSQI will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sleep-wake pattern
Časové okno: Daily measurements - for the whole duration of follow-up (2 months)
|
Sleep-wake pattern will be estimated based on measurements of movement and heart rate obtained from a wearable device (wristband).
|
Daily measurements - for the whole duration of follow-up (2 months)
|
|
Heart Rate
Časové okno: Heart Rate will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Heart rate will be measured using ECG.
|
Heart Rate will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
The personal ambient temperature profile of all participants
Časové okno: Daily measurements - for the whole duration of follow-up (2 months)
|
Personal exposures of participants will be monitored continuously during the two observation months with wearable sensors to be always worn and assess personal exposure to ambient (indoor and outdoor) temperature (iButton).
|
Daily measurements - for the whole duration of follow-up (2 months)
|
|
Serum Urea Levels
Časové okno: Serum levels of urea will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of urea (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of urea will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Creatinine Levels
Časové okno: Serum levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of creatinine (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Sodium levels
Časové okno: Serum levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of sodium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Osmolality
Časové okno: Serum osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum osmolality (mOsm/kg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Creatinine Levels
Časové okno: Urine levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of creatinine (mg/dL), as a marker of renal function, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of creatinine will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Sodium levels
Časové okno: Urine levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of sodium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of sodium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Potassium levels
Časové okno: Urine levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of potassium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Urine Osmolality
Časové okno: Urine osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine osmolality (mOsm/kg), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Urine osmolality will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Sleep-Wake self-reported evaluation
Časové okno: The sleep-wake self-reported evaluation will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The sleep-wake self-reported evaluation will be carried out using a predefined sleep diary which will be completed by the participant on the morning after he/she wakes up.
Each assessment of sleep-wake self-reported evaluation will be carried out for a whole week.
|
The sleep-wake self-reported evaluation will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Hamilton Anxiety Rating Scale
Časové okno: The Hamilton Anxiety Rating Scale will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
The Hamilton Anxiety Rating Scale will be carried out to assess the severity of a person's anxiety.
The Hamilton Anxiety Rating Scale ranges from 0 to 56, where higher scores indicate greater anxiety severity.
The scoring is divided into severity tiers: <17 (mild), 18-24 (mild to moderate), and 25-56 (moderate to severe).
The scale consists of 14 items, each rated from 0 to 4 points.
It evaluates both psychic anxiety (e.g., tension, fears, mood) and somatic anxiety (physical complaints).
|
The Hamilton Anxiety Rating Scale will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Daily heart rate
Časové okno: Daily measu.ments - for the whole duration of follow-up (2 months) .
|
Heart rate measurements taken throughout the day by a wearable device (wristband).
|
Daily measu.ments - for the whole duration of follow-up (2 months) .
|
|
Systolic/Diastolic Blood Pressure
Časové okno: Systolic/Diastolic blood pressure will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Measurements of Systolic/Diastolic Blood Pressure will be recorded.
|
Systolic/Diastolic blood pressure will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Heart Rate Variability
Časové okno: The heart rate variability will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Heart rate variability will be measured using ECG.
|
The heart rate variability will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum C-reactive Protein Levels
Časové okno: Serum levels of C-reactive protein will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of C-reactive protein (mg/L), as a marker of systemic inflammation, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of C-reactive protein will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Serum Potassium Levels
Časové okno: Serum levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of potassium (mmol/L), as a marker of hydration, will be measured from each participant at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
Serum levels of potassium will be assessed at baseline, middle (after 1 month), and at end of observation period (after 2 months).
|
|
Wet-bulb globe temperature (WGBT)
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Wet-bulb globe temperature, will be assessed as a thermal stress indicator.
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Humidity
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Humidity will be measured using iButton.
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 2.5 (PM 2.5) at residence
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM2.5 (micrograms per cubic meter of air) at participants' residences will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 2.5 (PM 2.5) at work
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM2.5 (micrograms per cubic meter of air) at participants' work place will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 10 (PM 10) at residence
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM10 (micrograms per cubic meter of air) at participants' residences will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Indoor concentration levels of Particulate Matter 10 (PM 10) at work
Časové okno: Daily measurements - for the whole duration of follow-up (2 months).
|
Indoor concentration levels of PM10 (micrograms per cubic meter of air) at participants' work place will be measured continuously indoors using commercial lightweight sensors (Alpha sense).
|
Daily measurements - for the whole duration of follow-up (2 months).
|
|
Number of daily steps
Časové okno: Daily measurements - for the whole duration of follow-up (2 months)
|
Number of daily steps will be measured throughout the day by a wearable device (wristband).
|
Daily measurements - for the whole duration of follow-up (2 months)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Panayiotis Yiallouros, Professor, University of Cyprus
Publikace a užitečné odkazy
Obecné publikace
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x. No abstract available.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci nervového systému
- Duševní poruchy
- Poruchy spánku a bdění
- Poruchy spánku, vnitřní
- Dysomnie
- Poruchy iniciace a udržování spánku
- Veřejné zdraví
- Životní prostředí a veřejné zdraví
- Fyzické jevy
- Prostředí
- Ekologické a environmentální jevy
- Biologické jevy
- Termodynamika
- Počasí
- Atmosféra
- Meteorologické koncepty
- Teplota
- Znečištění životního prostředí
- Horká teplota
- Air Pollution
Další identifikační čísla studie
- 101156653.LL2.PW
- 101156653 (Jiný identifikátor: European Commission)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Heat intervention
-
Boston Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...DokončenoDětská obezita | Technologická intervence proti obezitěSpojené státy
-
dorsaVi LtdMonash UniversityDokončeno
-
University of RochesterNational Cancer Institute (NCI)Zatím nenabírámeRakovina prsu | Únava související s rakovinouSpojené státy
-
University Hospital, ToulouseUkončeno
-
The University of Texas Health Science Center at...Congressionally Directed Medical Research ProgramsNáborSCI - Poranění míchySpojené státy
-
University of Illinois at Urbana-ChampaignDokončeno
-
University of California, DavisThrasher Research Fund; California Department of Health Services; University...Dokončeno
-
Oregon Research InstituteDokončenoZneužívání návykových látekSpojené státy
-
Sarah BlaylockVA Office of Research and DevelopmentDokončenoPodzim | Nízké viděníSpojené státy
-
Johns Hopkins UniversityAga Khan University; Aman FoundationDokončenoNemoc z horka | Teplo | Vystavení teplu | Úpal | Tepelné vyčerpání | Teplotní synkopa, Sequela | Tepelný kolaps | Úpal a úpalPákistán